Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key...

Published on 22 Sep 2024 on Insider Monkey · via Yahoo Finance

Scout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Small...

Read the rest of the article

Start tracking your investments with Statfolio

On Tuesday, Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) revealed the topline data from the Phase...

Benzinga · via Yahoo Finance 19 Feb 2025

Total Revenue: $175.7 million for Q3 2024, up from $153.9 million in Q3 2023. Net Product Sales:...

GuruFocus.com · via Yahoo Finance 5 Nov 2024

Supernus Pharmaceuticals Inc (SUPN) reports a 32% revenue increase, driven by Qelbree and Gocovri...

GuruFocus.com · via Yahoo Finance 9 Oct 2024

Piper Sandler downgraded Supernus Pharmaceuticals Inc (NASDAQ:SUPN), saying that the anticipated...

Benzinga · via Yahoo Finance 22 Sep 2024

Scout Investments, Inc, an affiliate of Carillon Tower Advisers, released the “Carillon Scout Sma...

Insider Monkey · via Yahoo Finance 22 Sep 2024

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript May 8, 2024 Supernu...

Insider Monkey via Yahoo Finance 6 May 2024

The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, ...

Entrpreneur 10 Apr 2024

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a company specializing in CNS diseases, has receive...

Investing.com 9 Apr 2024

On Monday, Supernus Pharmaceuticals Inc. (NASDAQ:SUPN) announced a regulatory update for SPN-830,...

Benzinga via Yahoo Finance 8 Apr 2024

The U.S. Food and Drug Administration (FDA) declined to approve Supernus Pharmaceuticals'...

Reuters 8 Apr 2024